RTP Mobile Logo
Select Publications

Al-Ali HK et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol 2020;189(5):888-903. Abstract

Gill H et al. A phase 2 study of the LSD1 inhibitor img-7289 (bomedemstat) for the treatment of advanced myelofibrosis. ASH 2021;Abstract 139.

Goulart H et al. Low-risk polycythemia vera and essential thrombocythemia: Management considerations and future directions. Ann Hematol 2022;101(5):935-51. Abstract

Gupta V et al. Safety and tolerability of fedratinib (fedr), an oral inhibitor of Janus kinase 2 (jak2), in patients with intermediate- or high-risk myelofibrosis (mf) previously treated with ruxolitinib (rux): Results from the phase 3b FREEDOM trial. ASH 2021;Abstract 389.

Harrison C et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Eng J Med 2012;366(9):787-98. Abstract

Harrison C et al. Overall and progression-free survival in patients treated with fedratinib as first-line myelofibrosis (MF) therapy and after prior ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 trials. EHA 2021;Abstract S203.

Harrison CN et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol 2022;40(15):1671-80. Abstract

Harrison CN et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKART-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4(7):e317-24. Abstract

Harrison CN et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016;30(8):1701-7. Abstract

Harrison CN et al. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis. ASH 2021;Abstract 3649.

Harrison CN et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY-2): A randomised, open-label, phase 3 trial. Lancet Haematol 2018:5(2):e73-81. Abstract

Harrison CN et al. Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). ASCO 2017;Abstract 7001.

Harrison CN et al. Real-world utilization of fedratinib for myelofibrosis post-ruxolitinib: Patient characteristics, treatment patterns, and characterization of ruxolitinib failure. ASH 2021;Abstract 3059.

Hobbs G et al. PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Adv 2021;5(23):5086-97. Abstract

Hoffman R et al. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. ASCO 2022;Abstract 7003.

Kremyanskaya M et al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis – Update of clinical and translational data from the ongoing Manifest trial. ASH 2021;Abstract 141.

Kuykendall AT et al. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Ann Hematol 2022;101(1):139-46. Abstract

Mascarenhas J et al. A randomized open label, phase 3 study of evaluate imetelstat versus best available therapy (BAT) in patients with intermediate-2 (int-2) or high-risk myelofibrosis (MF) refractory to Janus kinase inhibitor (JAKi). ASH 2021;Abstract 1503.

Mascarenhas J et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 2018;4(5):652-9. Abstract

Mascarenhas J et al. Paradigm shift: Combination BET and JAK inhibition in myelofibrosis. Leukemia 2021;35(12):3361-3. Abstract

Mascarenhas J et al. Randomized, single-blind, multicenter, phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol 2021;39(26):2881-92. Abstract

Mascarenhas J et al. Retrospective head-to-head comparison between pacritinib and ruxolitinib in patients with myelofibrosis and moderate-to-severe thrombocytopenia. ASH 2021;Abstract 3639.

Mascarenhas J et al. Safety analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. ASH 2021;Abstract 3640.

Mascarenhas J et al. Treatment of myelofibrosis patients with the TGF-beta 1/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production. ASH 2021;Abstract 142.

Mascarenhas JO, Verstovsek S. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. Cancer 2022;[Online ahead of print]. Abstract

Mesa RA et al. INDEPENDENCE: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on jak2 inhibitor therapy and requiring red blood cell transfusions. ASH 2021;Abstract 1490.

Mesa RA et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.

Mesa RA et al. Pacritinib demonstrates efficacy versus best available therapy in myelofibrosis patients with severe thrombocytopenia in two phase 3 studies. ASH 2019;Abstract 419.

Mesa RA et al. Pacritinib versus bet available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial. Lancet Haematol 2017;4(5):e225-36. Abstract

Mesa RA et al. SIMPLIFY-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. J Clin Oncol 2017;35(34):3844-50. Abstract

Nathan DI et al. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future. Leuk Res 2022;115:106820. Abstract

Palmer JM et al. The impact of pacritinib on myelofibrosis symptoms in patients with moderate and severe thrombocytopenia: A retrospective analysis of patients in the Persist-2 study. ASH 2021;Abstract 3628.

Pardanani A et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 2015;1(5):643-51. Abstract

Pardanani A et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol 2021;195(2):244-8. Abstract

Sastow D et al. Thrombocytopenia in patients with myelofibrosis: Pathogenesis, prevalence, prognostic impact, and treatment. Clin Lymphoma Myeloma Leuk 2022;[Online ahead of print]. Abstract

Srisuwananukorn A et al. Novel machine learning algorithm predicts disease progression in polycythemia vera (PV) with readily-available baseline characteristics. ASH 2021;Abstract 2583.

Tremblay D et al. Mild anemia as a single independent predictor of morality in patients with COVID-19. EJHaem 2021;[Online ahead of print]. Abstract

Tremblay D et al. The effect of fedratinib, a selective inhibitor of Janus kinase 2, on weight and metabolic parameters in patients with intermediate- or high-risk myelofibrosis. Clin Lymphoma Myeloma Leuk 2022;[Online ahead of print]. Abstract

Tremblay D, et al. Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res 2021:109:106629. Abstract

Tremblay D, Mascarenhas J. Next generation therapeutics for the treatment of myelofibrosis. Cells 2021;10(5):1034. Abstract

Vachhani P et al. Disease modification in myelofibrosis: An elusive goal? J Clin Oncol 2022;40(11):1147-55. Abstract

Varricchio L et al. TGF-beta1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight 2021;6(18):e145651. Abstract

Vianelli N et al. A randomized, phase 3 trial of fedratinib versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis previously treated with ruxolitinib (FREEDOM2). ASH 2021;Abstract 3643.

Venugopal S et al. Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences. Blood Reviews 2021;46:100735. Abstract

Venugopal S, Mascarenhas J. Current clinical investigations in myelofibrosis. Hematol Oncol Clin North Am 101;35(2):353-73. Abstract

Verstovek S et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807. Abstract

Verstovsek S et al. BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF). ASCO 2021;Abstract TPS7057.

Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10(1):156. Abstract

Verstovsek S et al. MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Future Oncol 2021;17(12):1449-58. Abstract

Verstovsek S et al. Robust overall survival and sustained efficacy outcomes during long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate/high risk myelofibrosis patients. ASH 2020;Abstract 54.

Waksal JA et al. Clinical utility of fedratinib in myelofibrosis. Onco Targets Ther 2021;14:4509-21. Abstract

Waksal JA et al. Novel therapeutics and targets in myelofibrosis. Leuk Lymphoma 2022;63(5):1020-33. Abstract

Yacoub A et al. A randomized, double-blind, placebo-controlled phase 3 study of add-on parsaclisib in patients with myelofibrosis who have suboptimal response to ruxolitinib. ASH 2021;Abstract 1502.

Yacoub A et al. Subgroup analysis from a phase 2 study of the efficacy and safety of parsaclisib, a selective PI3KD inhibitor, in combination with ruxolitinib in patients with myelofibrosis (MF). ASH 2021;Abstract 3647.

Zhou S et al Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms. Acta Haematol 2021;144(1):48-57. Abstract